[go: up one dir, main page]

PL2894162T3 - Identyfikacja związanych z nowotworem antygenów do diagnozowania i leczenia - Google Patents

Identyfikacja związanych z nowotworem antygenów do diagnozowania i leczenia

Info

Publication number
PL2894162T3
PL2894162T3 PL15153951T PL15153951T PL2894162T3 PL 2894162 T3 PL2894162 T3 PL 2894162T3 PL 15153951 T PL15153951 T PL 15153951T PL 15153951 T PL15153951 T PL 15153951T PL 2894162 T3 PL2894162 T3 PL 2894162T3
Authority
PL
Poland
Prior art keywords
tumor
diagnosis
therapy
identification
associated antigens
Prior art date
Application number
PL15153951T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Michael Koslowski
Dirk Usener
Original Assignee
Ganymed Pharmaceuticals Gmbh
Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Gmbh, Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten filed Critical Ganymed Pharmaceuticals Gmbh
Publication of PL2894162T3 publication Critical patent/PL2894162T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
PL15153951T 2005-09-12 2006-09-06 Identyfikacja związanych z nowotworem antygenów do diagnozowania i leczenia PL2894162T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20050019786 EP1762575A1 (en) 2005-09-12 2005-09-12 Identification of tumor-associated antigens for diagnosis and therapy
EP20110003883 EP2433954B8 (en) 2005-09-12 2006-09-06 Identification of tumor-associated antigens for diagnosis and therapy
EP06791878.9A EP1924600B1 (en) 2005-09-12 2006-09-06 Identification of tumor-associated antigens for diagnosis and therapy
EP15153951.7A EP2894162B1 (en) 2005-09-12 2006-09-06 Identification of tumor-associated antigens for diagnosis and therapy

Publications (1)

Publication Number Publication Date
PL2894162T3 true PL2894162T3 (pl) 2018-06-29

Family

ID=35285406

Family Applications (3)

Application Number Title Priority Date Filing Date
PL06791878T PL1924600T3 (pl) 2005-09-12 2006-09-06 Identyfikacja związanych z nowotworem antygenów do diagnozowania i leczenia
PL15153951T PL2894162T3 (pl) 2005-09-12 2006-09-06 Identyfikacja związanych z nowotworem antygenów do diagnozowania i leczenia
PL11003883T PL2433954T3 (pl) 2005-09-12 2006-09-06 Identyfikacja związanych z nowotworem antygenów w celu diagnozowania i leczenia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06791878T PL1924600T3 (pl) 2005-09-12 2006-09-06 Identyfikacja związanych z nowotworem antygenów do diagnozowania i leczenia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11003883T PL2433954T3 (pl) 2005-09-12 2006-09-06 Identyfikacja związanych z nowotworem antygenów w celu diagnozowania i leczenia

Country Status (21)

Country Link
US (5) US20090202530A1 (pl)
EP (14) EP1762575A1 (pl)
JP (5) JP6037593B2 (pl)
KR (2) KR101359697B1 (pl)
CN (1) CN101305020B (pl)
AU (1) AU2006291717B2 (pl)
BR (1) BRPI0616827A2 (pl)
CA (2) CA2620712A1 (pl)
CY (3) CY1114661T1 (pl)
DK (3) DK2894162T3 (pl)
ES (4) ES2664386T3 (pl)
HK (3) HK1168608A1 (pl)
HR (3) HRP20131047T1 (pl)
HU (1) HUE037307T2 (pl)
LT (1) LT2894162T (pl)
PL (3) PL1924600T3 (pl)
PT (3) PT1924600E (pl)
RS (3) RS53009B (pl)
RU (2) RU2485974C2 (pl)
SI (3) SI1924600T1 (pl)
WO (1) WO2007031222A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
AU2013206613B2 (en) * 2005-09-12 2017-03-02 Biontech Ag Identification of tumor-associated antigens for diagnosis and therapy
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
AU2016201637B2 (en) * 2007-10-23 2017-05-25 Biontech Ag Identification of tumor-associated markers for diagnosis and therapy
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
AU2015205868B2 (en) * 2008-09-16 2017-04-27 Ganymed Pharmaceuticals Ag Monoclonal antibodies for treatment of cancer
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
WO2011151471A1 (en) * 2010-06-04 2011-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel immunoadjuvant compounds and uses thereof
FI3892295T3 (fi) 2011-05-24 2023-05-10 BioNTech SE Yksilöityjä rokotteita syöpää varten
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
MX2016010177A (es) 2014-02-07 2017-01-09 Dong Wha Pharm Co Ltd Composicion adyuvante anticancerosa que contiene promotor de la expresion de rip3 como principio activo, metodo para la deteccion de adyuvante anticanceroso que potencia la sensibilidad al farmaco anticanceroso mediante la estimulacion de la expresion de rip3 y metodo para controlar la sensibilidad del farmaco anticanceroso.
WO2016040682A1 (en) 2014-09-10 2016-03-17 Genentech, Inc. Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
RU2620306C2 (ru) * 2015-01-15 2017-05-24 Олег Викторович Бухтояров Способ прогнозирования рецидива злокачественного опухолевого заболевания
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
AU2016232280B2 (en) * 2015-03-16 2018-05-31 Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
MX2017015927A (es) * 2015-06-16 2018-04-18 Targovax Asa Fragmentos mutantes de proteina ras.
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
WO2017127716A1 (en) 2016-01-22 2017-07-27 Temple University-Of The Commonwealth System Of Higher Education Protein quantification by near infrared spectral imaging
CN107266552B (zh) * 2016-03-30 2022-02-08 香雪生命科学技术（广东）有限公司 源自于prame的肿瘤抗原短肽
KR102344619B1 (ko) 2016-05-20 2021-12-31 아란세오 네덜란즈 비.브이. 고무 조성물
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术（广东）有限公司 源自于mage b6的肿瘤抗原短肽
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
JP7082556B2 (ja) 2018-09-28 2022-06-08 三和シヤッター工業株式会社 シャッター装置

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5744585A (en) * 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
JP4774551B2 (ja) * 1999-01-13 2011-09-14 アルトロパス ゲーエムベーハー 抗癌ワクチン接種のための抗体の使用
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
DK1309726T4 (en) 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
AU2001280608A1 (en) * 2000-07-18 2002-01-30 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
US20020177547A1 (en) * 2001-01-16 2002-11-28 Karin Molling Pharmaceutical compositions for treating or preventing cancer
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2005507239A (ja) * 2001-05-25 2005-03-17 インサイト・ゲノミックス・インコーポレイテッド 分泌タンパク質
EP1478772A2 (en) * 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
AU2003209459A1 (en) 2002-03-06 2003-09-16 Hybrigenics Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2003102159A2 (en) * 2002-06-04 2003-12-11 Curagen Corporation Novel proteins and nucleic acids encoding same
US7053201B2 (en) * 2002-08-30 2006-05-30 National Defense Medical Center Nucleic acid molecules and polypeptides related to h-ADAM7
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
KR20090088973A (ko) 2002-10-17 2009-08-20 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
AU2003291399A1 (en) * 2002-11-06 2004-06-03 Sequenom, Inc. Methods for identifying risk of melanoma and treatments thereof
JP4624977B2 (ja) * 2003-01-17 2011-02-02 ザ チャイニーズ ユニバーシティ オブ ホンコン 妊娠障害診断マーカーとしての血中ｍＲＮＡ
EP1592811A2 (en) * 2003-02-11 2005-11-09 Wyeth Methods for monitoring drug activities in vivo
WO2005049806A2 (en) * 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
RU2256924C2 (ru) * 2003-09-03 2005-07-20 Торопова Надежда Ефимовна Способ дифференциальной диагностики злокачественных опухолей простаты
WO2005079490A2 (en) * 2004-02-13 2005-09-01 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
CN1663603A (zh) * 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
NZ594480A (en) 2009-02-20 2013-11-29 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer

Also Published As

Publication number Publication date
JP2009507868A (ja) 2009-02-26
ES2535500T3 (es) 2015-05-12
SI2433954T1 (sl) 2015-06-30
HRP20131047T1 (hr) 2013-12-06
AU2006291717B2 (en) 2013-06-06
US20140017254A1 (en) 2014-01-16
HK1211606A1 (en) 2016-05-27
EP2894162B1 (en) 2018-01-03
EP2433954A2 (en) 2012-03-28
EP2433961A3 (en) 2012-06-27
CY1114661T1 (el) 2016-10-05
CY1116951T1 (el) 2017-04-05
EP2433960B1 (en) 2015-03-04
SI2894162T1 (en) 2018-05-31
EP2966082A1 (en) 2016-01-13
EP2433956A3 (en) 2012-07-04
EP2966082B1 (en) 2017-08-30
EP2433962A2 (en) 2012-03-28
EP2433957A2 (en) 2012-03-28
KR20130121198A (ko) 2013-11-05
JP2016102116A (ja) 2016-06-02
EP2433962B1 (en) 2015-03-25
WO2007031222A3 (en) 2007-07-26
EP2433960A2 (en) 2012-03-28
ES2532410T3 (es) 2015-03-26
EP2433962A3 (en) 2012-07-04
HK1118840A1 (en) 2009-02-20
EP2433958A2 (en) 2012-03-28
EP2433957A3 (en) 2012-07-04
HUE037307T2 (hu) 2018-08-28
CN101305020A (zh) 2008-11-12
CA2820201A1 (en) 2007-03-22
PT2894162T (pt) 2018-04-02
CY1120096T1 (el) 2018-12-12
RU2485974C2 (ru) 2013-06-27
JP2016166175A (ja) 2016-09-15
EP2433958B1 (en) 2015-02-25
US20110189179A1 (en) 2011-08-04
WO2007031222A2 (en) 2007-03-22
JP2015120691A (ja) 2015-07-02
SI1924600T1 (sl) 2013-12-31
DK2433954T3 (en) 2015-05-04
EP2433955A3 (en) 2012-07-04
PL1924600T3 (pl) 2014-01-31
EP2433954A3 (en) 2012-07-04
ES2434945T3 (es) 2013-12-18
EP2433961A2 (en) 2012-03-28
EP1762575A1 (en) 2007-03-14
RU2644686C2 (ru) 2018-02-13
KR101359697B1 (ko) 2014-02-07
JP5913547B2 (ja) 2016-04-27
JP2013136579A (ja) 2013-07-11
EP1924600A2 (en) 2008-05-28
ES2664386T3 (es) 2018-04-19
DK2894162T3 (en) 2018-04-16
PL2433954T3 (pl) 2015-07-31
AU2006291717A1 (en) 2007-03-22
RU2013113439A (ru) 2014-10-10
DK1924600T3 (da) 2013-11-11
EP1924600B1 (en) 2013-08-28
RU2008114318A (ru) 2009-10-20
EP2433955A2 (en) 2012-03-28
RS53009B (en) 2014-04-30
HK1168608A1 (en) 2013-01-04
LT2894162T (lt) 2018-04-10
EP2433959A3 (en) 2012-06-27
HRP20150432T1 (hr) 2015-09-25
EP2433954B8 (en) 2015-05-13
US9919036B2 (en) 2018-03-20
US20150197576A1 (en) 2015-07-16
EP2902412A1 (en) 2015-08-05
EP2433954B1 (en) 2015-02-25
CA2620712A1 (en) 2007-03-22
EP2894162A1 (en) 2015-07-15
RS53988B1 (en) 2015-10-30
PT1924600E (pt) 2013-11-18
EP2433958A3 (en) 2012-07-04
JP6037593B2 (ja) 2016-12-07
EP2433960A3 (en) 2012-07-04
HRP20180507T1 (hr) 2018-05-04
EP2433956A2 (en) 2012-03-28
EP2902412B1 (en) 2018-02-21
RS57080B1 (sr) 2018-06-29
CN101305020B (zh) 2015-09-02
JP5750433B2 (ja) 2015-07-22
CA2820201C (en) 2018-07-17
JP6196338B2 (ja) 2017-09-13
KR20080052664A (ko) 2008-06-11
US8975375B2 (en) 2015-03-10
US20090202530A1 (en) 2009-08-13
PT2433954E (pt) 2015-06-02
US20170080068A1 (en) 2017-03-23
BRPI0616827A2 (pt) 2011-07-05
EP2433959A2 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
HK1211606A1 (en) Identification of tumor-associated antigens for diagnosis and therapy
IL225386A0 (en) Diagnosis and treatment of cancer using anti-ereg antibody
HUS1700015I1 (hu) PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1811844A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
HRP20140271T1 (hr) Humana antitijela protiv bjesnoä†e i njihova uporaba
PT1814580T (pt) Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais
HK1199887A1 (en) Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49
IL185491A0 (en) Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
EP1718145A4 (en) CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
IL179811A0 (en) Identification of tumors
EP1937816A4 (en) CANCER DIAGNOSTIC MARKERS AND USE
HK1117780A1 (en) Compounds and methods for the treatment of cancer
EP1742654A4 (en) ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER
IL185900A0 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200706159B (en) Compositions and methods for the diagnosis and treatment of tumor
IL201880A0 (en) Klotho protein and related compounds for the treatment and diagnosis of cancer
GB0511078D0 (en) Means and methods of verification of entitlement and identification
GB0421917D0 (en) Cancer diagnosis and therapy
ZA200710321B (en) Compositions and methods for the diagnosis and treatment of tumor